Health & Science

In recent days, a top Senate Republican has said that the coronavirus testing the United States has done so far is "not nearly enough."

The few planes that are flying are almost empty. To try to ensure the safety of the passengers they do have, airlines are making changes.

The Senate's top Democrat said the VA needs to provide Congress more information about a recent bulk order for $208,000 worth of hydroxychloroquine.

Lancaster, Schuylkill, Lebanon and Dauphin counties have all announced plans to move from the more restrictive “red” phase to “yellow.”

Widespread availability of testing is seen as critical to reopening the economy because it would allow public health officials to identify and contain a rebound of the virus.

With no guarantee they can collect unemployment if they refuse to go to work, immunocompromised workers fear a near-impossible choice: Risk losing their jobs, or their life.

The White House's concern about infection is another stark reminder that not even one of the nation’s most secure buildings is immune from the coronavirus.

By Monday, at least 31 states will have partially reopened after seven weeks of restrictions.

Companies around the country are figuring out how to safely reopen office during the pandemic. The new normal might involve smartphone apps and badges to track employees.

When the pill was approved in 1960, women had few relatively few contraceptive options, and the pill offered more reliability and convenience than methods like condoms.

Reopening too soon could exacerbate the already devastating death toll in long-term care facilities, they say.

Similar measures to those envisioned were later put in place, but only after widespread outbreaks were already underway.

The test will enable people to collect their own saliva at home and send it to a lab for results, while the drug has helped some COVID-19 patients improve.

Gilead has donated its existing supply, to be distributed by AmerisourceBergen. That company says the government decides which places can get the drug.

There are studies looking at changes to the virus genome — and the possible impact on how the virus affects humans. Here's what we know (and don't yet know) about mutations.